ArticleCancer research2008
Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- The dual role of complement in cancer and its implication in anti-tumor therapy.Annals of translational medicine · 2016Review
- NRSF: an angel or a devil in neurogenesis and neurological diseases.Journal of molecular neuroscience : MN · 2015Review
- The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage.International journal of molecular sciences · 2014Article
- Retraction: Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.Cancer research · 2013Article
- Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.Cellular & molecular immunology · 2011Article
- Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation.Nucleic acids research · 2010Article
- Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration.The pharmacogenomics journal · 2010Article
- Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Implication of complement system and its regulators in Alzheimer's disease.Current neuropharmacology · 2009Article
- New insights of an old defense system: structure, function, and clinical relevance of the complement system.Molecular medicine (Cambridge, Mass.)Review
Corrections and comments
- Retraction · 2013-11-15Falsification/Fabrication of Image · Investigation by Company/Institution ·
- Retracted
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Tumor cells escape clearance by complement by abundantly expressing CD59 and other membrane complement regulators. Existing strategies for blocking/knocking down these regulators can contribute to tumor immunoclearance in vitro; however, there are numerous difficulties restricting their use in vivo. Here, we report a new strategy for suppression of CD59 expression in neuroblastoma using peptides that target regulators of CD59 expression. We identified the neural-restrictive silencer factor (REST) as a target for modulation of CD59 expression in neuroblastoma. We next designed plasmids that encoded peptides comprising different DNA-binding domains of REST and transfected them into neuroblastoma cell lines. These peptides suppressed CD59 expression, sensitizing neuroblastoma to complement-mediated killing triggered by anti-GD2 therapeutic monoclonal antibody. These CD59-modulating peptides might be effective therapeutic adjuvants to therapeutic monoclonal antibodies used for treatment of neuroblastoma and other cancer types sharing the same mechanism for regulation of CD59 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.